Enhanced Wound Healing System with Controlled Release of Multiple Therapeutic Proteins

A novel system for delivering multiple therapeutic proteins to enhance wound healing, featuring a hydrogel with a controlled release profile modulated by pH-dependent coacervates of polycationic and polyanionic polymers.

The original patent disclosed a composition comprising a hydrogel with embedded coacervates of multiple therapeutic proteins. However, the release profile of these proteins was not controlled, which limited the efficacy of the treatment. The new inventive concept addresses this limitation by introducing a pH-dependent coacervate that modulates the release profile, ensuring a more efficient and effective wound healing process.

The enhanced wound healing system consists of a hydrogel matrix with embedded coacervates of multiple therapeutic proteins, including fibroblast growth factor 2 (FGF-2) and stromal cell-derived factor 1 alpha (SDF-1α). The coacervates are formed by the interaction of polycationic and polyanionic polymers, which are designed to respond to changes in pH. As the wound environment changes, the pH-dependent coacervates release the therapeutic proteins in a controlled and sequential manner, mimicking the natural wound healing process. This controlled release profile ensures that the proteins are delivered at the optimal time and concentration, enhancing the wound healing response.

The new inventive concept introduces a novel pH-dependent coacervate that modulates the release profile of the therapeutic proteins, which is not disclosed in the original patent. This controlled release profile is a significant improvement over the original composition, as it ensures a more efficient and effective wound healing process.

Alternative embodiments of the inventive concept include the use of different types of polymers, such as polyethylene glycol or chitosan, to form the coacervates. Additionally, the system could be designed to release other therapeutic proteins or growth factors, such as vascular endothelial growth factor (VEGF) or keratinocyte growth factor (KGF).

The enhanced wound healing system has significant commercial potential in the wound care market, which is projected to reach $22.8 billion by 2025. The system could be used in a variety of clinical settings, including hospitals, clinics, and long-term care facilities, to treat acute and chronic wounds.